Navigation Links
$6.37 million from National Institutes of Health to find new ways to treat psoriasis
Date:11/6/2007

The National Institute of Arthritis and Musculoskeletal Skin Diseases (NIAMS), a research center at the National Institutes of Health (NIH), has awarded Case Western Reserve University School of Medicine and University Hospitals Case Medical Center a $6.37 million award to establish a Center of Research Translation (CORT) for the skin disease psoriasis.

This is one of the largest grants ever given to a medical institution in the United States for the study of psoriasis.

With a five-year grant from NIAMS, the Psoriasis CORT will bring a multidisciplinary team of translational physicians scientists, nurses, community clinicians, laity and basic scientists from different departments and disciplines together. This team will apply the intellectual and scientific resources of their institutions to new therapies to provide relief to patients with the skin disease that has long-term health and psychosocial consequences.

Our goal is to find ways to rebalance the human bodys immune system and skin cells to restrain the expression of this skin disease, said Kevin Cooper, M.D., department chair of dermatology at University Hospitals Case Medical Center (UHCMC) and professor of dermatology at the Case Western Reserve University School of Medicine. It is very important to obtain safe and durable remissions from disease because psoriasis has significant impact on patient health, spanning psychosocial effects, and risk for long-term cardiovascular complications and cancers.

The CORT grant complements a $5 million gift to University Hospitals Case Medical Center (UHCMC) from The Murdough Foundation that was received in December 2006 designed to advance the research and treatment of psoriasis. The gift remains the largest known in the United States for dermatology at an academic medical center. The Murdough Family Center for Psoriasis supports and stimulates clinical research and treatment for, and education about, psoriasis and creates a critical base for the CORT research projects and cores.

Together with the recently awarded $64 million NIH Clinical Translational Services Award to Case Western Reserve University and the NIH NIAMS Skin Diseases Research Center at Case Medical Center, the Psoriasis CORT concentrates a remarkable array of interactive research resources that we expect to change patient care with safer and better therapies, said Pamela Davis, dean of the Case Western Reserve University School of Medicine.

This CORT award reinforces University Hospitals Case Medical Centers dedication to, and progress with both the treatment and research of psoriasis, said Fred C. Rothstein, M.D., president and CEO of University Hospitals Case Medical Center. Our unique interdisciplinary approach to psoriasis therapy and study places us at the forefront of eventually curing this debilitating disease.

The NIAMS grant will allow research teams to focus on three projects that simultaneously utilize different strategies to study the disease.

  • PROJECT ONE: Researchers will test and explore the potential use in psoriasis of PC4, a novel photodynamic therapy (PDT), developed as a treatment for skin cancer at Case Western Reserve University by Malcolm Kenney, Ph.D., from the department of chemistry; Nancy Oleinick, Ph.D; and Drs. Cooper and Elma Baron at UHCMC.

    In a clinical trial, the non-invasive photosensitizer PC4 will be applied topically and exposed to red light to active the light-sensitive chemicals. After treatment, a real-time analysis of the psoriasis tissue will take place with the aid of a newly built device to conduct optical monitoring of tissue oxygen levels during treatments. The goal is to control inflammation that eventually brings on T-cell damage.

  • PROJECT TWO: Another focus of the Psoriasis CORT is to understand the role that S100A8/9, a pro-inflammatory protein, has in initiating the biochemical processes that result in the production of T-cells. Approximately 50 patients a year will participate in this area of the study.

    The research team hypothesizes that S100A8/9 is associated with a molecular pattern that recruits, activates and differentiates macrophage cells in the skin of patients with psoriasis and that blocking these processes will halt the progression of the disease.

  • PROJECT THREE: Through a study of genetically engineered mice with disease characteristics of psoriasis, the researchers hope to analyze the biochemical processes that create the signals leading to the disease and formulate strategies to block the signals. They also hope to study the cardiovascular risks associated with this disease in this mouse model.

Case Western Reserve and UHCMC are recognized as leaders in the study of psoriasis in multiple ways; the Skin Disease Research Center, which is one of only six NIH/NIAMS centers throughout the entire country; the Murdough Family Center for Psoriasis; NIH NIAMS research project funding; Veterans Administration translational clinical trial funding; and now the Psoriasis CORT.


'/>"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: